Our study identifies that matrix stiffness-dependent STEAP3 and PD-L2 could be applied as the independent predictors to sorafenib response, and thus targeting it could be a potential diagnosis and treatment strategy for HCC. This evidence concerns the gene PDCD1LG2 and hepatocellular carcinoma.